Accord Healthcare Ltd.
https://www.accord-healthcare.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Accord Healthcare Ltd.
‘The US Is Catching Up’ – Accord’s Kokino On Biosimilar Market Dynamics
In the second part of his interview with Generics Bulletin, Chrys Kokino – president of Accord US – talks about how the US biosimilars market is catching up with Europe, as well as discussing aspects such as PBMs, the Inflation Reduction Act and biosimilar interchangeability.
‘We Are Going To Be Deeply Engaged In The Biosimilar Arena’ – Accord BioPharma Sets Out US Strategy
Hot on the heels of Accord BioPharma recently announcing a US filing for a Stelara biosimilar – as well as a settlement that will let it enter the market in May 2025 – Chrys Kokino, president of Accord US, talks about how the product fits into the firm’s wider biosimilars strategy in the first part of a two-part interview with Generics Bulletin.
Samsung Bioepis And Sandoz Get EU Nod For Stelara Rival
Samsung Bioepis has received an EMA nod for its Sandoz-partnered Stelara biosimilar under the name Pyzchiva. Meanwhile, the agency’s CHMP also recommended granting centralized marketing authorizations for two Accord generics.
Two Avian Flu Vaccines Among 10 New Products To Get EMA Nod
The European Medicines Agency has OKd two new H5N1 jabs, including a pandemic preparedness vaccine intended for use only if a flu pandemic is declared. Eight other products are also heading for EU-wide approval.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice